Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Bioavailability of Lu AG06474 in Healthy Young Volunteers
NCT05943327Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lu ag06474 in pain (3 arms), sponsored by Lundbeck. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events (AEs), Electrocardiogram (ECG) Parameter (delta QTcF) on Day 5 and 7 more. Started Jun 2023; status: terminated.
02
Drugs
lu ag06474
03
Conditions
pain
Beyond the preview
Go deeper on NCT05943327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943327.